Patents Assigned to Supernus Pharmaceuticals, Inc.
  • Trospium chloride treatment method
    Patent number: 7781449
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7781448
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Method of treating bladder dysfunction with once-a-day trospium salt formulation
    Patent number: 7759359
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 20, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily formulations of tetracyclines
    Patent number: 7749532
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Modified-release preparations containing oxcarbazepine and derivatives thereof
    Patent number: 7722898
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: May 25, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Osmotic delivery of therapeutic compounds by solubility enhancement
    Patent number: 7611728
    Abstract: The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: November 3, 2009
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Shimul K. Ray, Padmanabh P. Bhatt, Jones W. Bryan, Jr.
  • ENHANCED FORMULATIONS OF LAMOTRIGINE
    Publication number: 20090022789
    Abstract: A once-a-day, extended-release formulation of lamotrigine, exhibiting a significantly similar release rate throughout the GI tract irrespective of the pH of the environment, is provided. The formulation comprises lamotrigine, an organic acid, a release enhancing polymer and a release controlling polymer. The use of the formulation for the treatment of the neurological disorders is also disclosed.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 22, 2009
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Kevin Edwards, Padmanabh P. Bhatt
  • Once daily dosage forms of trospium
    Publication number: 20080207663
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207664
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207661
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Publication number: 20080207662
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 28, 2008
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Once daily dosage forms of trospium
    Patent number: 7410978
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: August 12, 2008
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Accelerated culture system for intestinal epithelial cell monolayers
    Patent number: 7300794
    Abstract: The present invention provides a unique medium for the cultivation of intestinal cell lines. The medium allows for the development of a highly differentiated intestinal epithelial cell monolayer in a much shorter period of time than currently possible without the aid of cell culture substrates.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: November 27, 2007
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Marina Lowen, Ali Keshavarz-Shokri